Globaldata's analysis focuses on three key indicators, which include HTA outcomes in the 5EU and the entry of newly priced ...

Haya Therapeutics has secured $65m in Series A funding to expedite the clinical development of HTX-001 for treating heart ...

NewBiologix has given a non-exclusive technology licence to Recipharm Advanced Bio to provide pharma companies access to ...

BioVaxys Technology and Sona Nanotech have signed an agreement to develop cancer therapeutics, utilising the DPX platform ...

HLS Therapeutics has signed an agreement with Esperion Therapeutics for commercialising Nexletol and Nexlizet in Canada.

The Vivo Opportunity Fund has already catalysed a plethora of medicine development via biotech investments in its first two ...

The US Food and Drug Administration (FDA) has set an "aggressive" timeline to implement genAI across the agency by 30 June ...

ARS Pharmaceuticals has announced the availability of neffy (epinephrine nasal spray) 1mg in the United States.

Viralgen has partnered biotech company Trogenix, aiming to accelerate the development of gene therapy for glioblastoma.

Apart from four billion-dollar deals valued at $1bn or more driven by large pharma, the industry remains cautious given the ...